X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (740) 740
oncology (679) 679
radiotherapy (455) 455
female (451) 451
male (432) 432
chemotherapy (373) 373
hyperfractionated radiotherapy (368) 368
middle aged (354) 354
aged (322) 322
adult (302) 302
combined modality therapy (297) 297
hyperfractionated radiation-therapy (247) 247
index medicus (246) 246
radiology, nuclear medicine & medical imaging (228) 228
cancer (227) 227
radiation-therapy (224) 224
treatment outcome (199) 199
antineoplastic combined chemotherapy protocols - therapeutic use (196) 196
radiotherapy dosage (192) 192
lung neoplasms - radiotherapy (178) 178
neoplasm staging (176) 176
survival rate (154) 154
surgery (152) 152
carcinoma, non-small-cell lung - radiotherapy (148) 148
dose fractionation (144) 144
care and treatment (143) 143
survival (136) 136
child (133) 133
survival analysis (133) 133
lung neoplasms - drug therapy (130) 130
prognosis (128) 128
adolescent (125) 125
cisplatin (125) 125
carcinoma (121) 121
squamous-cell carcinoma (121) 121
randomized trial (120) 120
tumors (114) 114
carcinoma, non-small-cell lung - drug therapy (110) 110
carcinoma, squamous cell - radiotherapy (108) 108
lung neoplasms - pathology (108) 108
follow-up studies (105) 105
trial (105) 105
concurrent chemotherapy (104) 104
head and neck neoplasms - radiotherapy (103) 103
aged, 80 and over (102) 102
radiation (102) 102
cisplatin - administration & dosage (101) 101
carcinoma, non-small-cell lung - pathology (100) 100
retrospective studies (99) 99
child, preschool (96) 96
children (96) 96
induction chemotherapy (95) 95
irradiation (95) 95
clinical neurology (92) 92
disease-free survival (90) 90
radiation therapy (89) 89
randomized-trial (89) 89
chemoradiotherapy (87) 87
hematology, oncology and palliative medicine (81) 81
antineoplastic agents - therapeutic use (80) 80
carcinoma, squamous cell - drug therapy (80) 80
glioma - radiotherapy (79) 79
hyperfractionated accelerated radiotherapy (79) 79
phase-iii trial (79) 79
head and neck neoplasms - drug therapy (78) 78
carboplatin (75) 75
toxicity (74) 74
brain neoplasms - radiotherapy (73) 73
gliomas (72) 72
head and neck cancer (72) 72
medicine & public health (71) 71
respiratory system (71) 71
hyperfractionated radiation (70) 70
prospective studies (70) 70
lung neoplasms - mortality (69) 69
research (67) 67
phase-ii (66) 66
chemotherapy, adjuvant (65) 65
antineoplastic combined chemotherapy protocols - adverse effects (64) 64
dose fractionation, radiation (63) 63
oncology-group (63) 63
pediatrics (63) 63
neck-cancer (61) 61
carcinoma, squamous cell - pathology (60) 60
accelerated radiotherapy (59) 59
analysis (59) 59
carcinoma, non-small-cell lung - mortality (59) 59
time factors (59) 59
therapy (58) 58
thoracic radiotherapy (58) 58
locally advanced head (57) 57
non-small cell lung cancer (57) 57
radiotherapy, adjuvant (55) 55
leukemia group-b (54) 54
pediatric-oncology-group (54) 54
radiotherapy - adverse effects (54) 54
therapy-oncology-group (54) 54
lung neoplasms - therapy (53) 53
chemoradiation (52) 52
lung cancer, non-small cell (52) 52
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (917) 917
French (15) 15
German (9) 9
Czech (2) 2
Chinese (1) 1
Italian (1) 1
Japanese (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Oncology, ISSN 0936-6555, 03/2019, Volume 31, Issue 3, pp. 171 - 181
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2006, Volume 24, Issue 7, pp. 1072 - 1078
Journal Article
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 82, Issue 1, pp. 425 - 434
Purpose Patients treated with chemoradiotherapy for locally advanced non–small-cell lung carcinoma (LA-NSCLC) were analyzed for local-regional failure (LRF)... 
Radiology | Hematology, Oncology and Palliative Medicine | Survival with respect to radiotherapy dose intensity | Local-regional failure | Radiation oncology | Chemoradiotherapy | Advanced non–small-cell lung carcinoma | Advanced non-small-cell lung carcinoma | LEUKEMIA GROUP-B | INDUCTION CHEMOTHERAPY | CONSOLIDATION DOCETAXEL | COMPETING RISK | FOLLOW-UP | CANCER | PHASE-III TRIAL | ONCOLOGY | HYPERFRACTIONATED RADIATION | CONCURRENT CHEMORADIATION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | THORACIC RADIOTHERAPY | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Treatment Failure | Aged, 80 and over | Adult | Female | Retrospective Studies | Paclitaxel - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Radiotherapy Dosage | Chemoradiotherapy - methods | Proportional Hazards Models | Carboplatin - administration & dosage | Etoposide - administration & dosage | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Non-Small-Cell Lung - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Amifostine - administration & dosage | Aged | Relative Biological Effectiveness | Medical colleges | Care and treatment | Carcinoma | Nuclear radiation | Patient outcomes | Lung cancer, Non-small cell | Radiotherapy | Cancer | Statistical analysis | Lung | Radiation | Clinical trials | Non-small cell lung carcinoma | Data processing | Dose-response effects | Oncology | Radiation therapy | Multivariate analysis | Survival | MULTIVARIATE ANALYSIS | PATIENTS | TESTING | FAILURES | LUNGS | CARCINOMAS | STANDARDS | RADIOLOGY AND NUCLEAR MEDICINE | RADIATION DOSES | RADIOTHERAPY | COMBINED THERAPY | HAZARDS | chemoradiotherapy | local-regional failure | Radiation Oncology | advanced non-small-cell lung carcinoma | survival with respect to radiotherapy dose intensity
Journal Article
Journal Article
Journal Article
Journal Article
Medical dosimetry : official journal of the American Association of Medical Dosimetrists, 06/2019
Nasopharyngeal adenoid cystic carcinoma is a rare neoplasm characterized by strong local invasiveness and a higher tendency to relapse. Because of the rare... 
Journal Article